[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypothermia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypothermia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,69,102,128,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100638477","esotip-tee-defining-an-easy-landmark-to-guide-correct-esophageal-probe-placement-with-transesophageal-echocardiography-100638477",false,"NCT07574736","ESOTIP-TEE: Defining an Easy Landmark to Guide Correct Esophageal Probe Placement With Transesophageal Echocardiography","ESOTIP-TEE","Inclusion Criteria:\n\n* Adult (≥18 years) patients admitted to the ICU\n* Clinical indication to perform a transesophageal echocardiography\n\nExclusion Criteria:\n\n* \\\u003C18 years","ALL",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to identify simple external anatomical landmarks that allow reliable prediction of correct esophageal probe insertion depth. Accurate placement in the lower third of the esophagus is essential for reliable core temperature monitoring. Transesophageal echocardiography (TEE) will be used as the reference standard to confirm correct probe position. The study will evaluate the agreement between landmark-based insertion depth and TEE-confirmed placement in adult ICU patients undergoing clinically indicated TEE.",[23,24,25],"Monitoring","Esophageal Temperature","Hypothermia","RECRUITING","2026-05-05",{"date":29,"type":30},"2026-05-08","ACTUAL",{"date":32,"type":30},"2025-12-12",{"date":34,"type":19},"2026-07-30",{"name":36,"class":37},"Institute of Mountain Emergency Medicine","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":38},"100604518","arch-clamping-technique-under-mild-hypothermia-in-treating-with-acute-type-a-aortic-dissection-100604518","NCT07150559","Arch-Clamping Technique Under Mild Hypothermia in Treating With Acute Type A Aortic Dissection","Arch-Clamping Technique Under Mild Hypothermia in Treating With Acute Type A Aortic Dissection: Study Protocol for a Multicenter, Three-arm, Open-label, Randomized, Parallel-controlled Trial","AHEAD","Inclusion Criteria:\n\n1. Aortic CTA confirmed as ATAAD according to the 2022 ACC\u002FAHA Guideline for the Diagnosis and Management of Aortic Disease;\n2. Adult patients (18-70 years) weighing 50-120 kg;\n3. Time interval between the onset of symptoms and operation is less than 14 days;\n4. Indications for total aortic arch replacement are available;\n5. Signed informed consent and availability for follow-up.\n\nExclusion Criteria:\n\n1. History of chronic renal failure, hepatocirrhosis, and hepatic insufficiency;\n2. Severe gastrointestinal complications of non-aortic dissection, such as mesenteric ischemia, gastrointestinal bleeding, hepatopancreaticobiliary dysfunction, and intestinal obstruction;\n3. History of severe cerebral infarction (with cerebral infarction sequels);\n4. Preoperative intubation or unconsciousness;\n5. Inflammatory aortic diseases, such as Takayasu arteritis and Behçet's disease, etc;\n6. History of infectious aortic diseases;\n7. History of cardiac and aortic surgery;\n8. History of malignancy or previous radiotherapy;\n9. Pregnant or feeding women, or anyone planning to reproduce during the test period;\n10. Without an informed consent signature;\n11. Participating in any other clinical trial;\n12. Having other causes not eligible for operation.","18 Years","70 Years",{"count":50,"type":19},306,"INTERVENTIONAL",[53],"NA","The study is a multicenter, three-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 306 participants diagnosed with acute type A aortic dissection (ATAAD) from 7 hospitals in China. All patients receive total arch replacement (TAR) combined with frozen elephant trunk (FET) implantation and are randomized to Group 1 (arch-clamping technique under mild hypothermia), Group 2 (arch-clamping technique under moderate hypothermia) and Group 3 (Sun's procedure using bilateral antegrade cerebral perfusion) in the ratio of 1:1:1. After a 1-year follow-up, the validity and safety of the mild hypothermic arch-clamping technique for ATAAD was evaluated via the incidence of major adverse events including death, renal replacement therapy, stroke, and paraplegia, as well as times of circulatory arrest, cardiopulmonary bypass, and mechanical ventilation, and length of ICU stay.",[56,25,57,58,59],"Acute Type A Aortic Dissection","Total Aortic Arch Replacement","Frozen Elephant Trunk","Bilateral Antegrade Cerebral Perfusion","2026-04-02",{"date":62,"type":30},"2026-04-06",{"date":64,"type":30},"2026-02-03",{"date":66,"type":19},"2028-02-28",{"name":68,"class":37},"Beijing Anzhen Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":51,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100518021","prehospital-resuscitation-intranasal-cooling-effectiveness-survival-study-2-100518021","NCT06025123","Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2","Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2 (PRINCESS2)","PRINCESS2","INCLUSION CRITERIA:\n\nPatients ≥18 years that meet all of the following inclusion criteria:\n\n1. Adult out-of-hospital cardiac arrest patients with initial shockable rhythm\n2. Unconsciousness defined as Glasgow Coma Scale \\\u003C 8\n3. Inclusion within 20 minutes from EMS arrival\n\nEXCLUSION CRITERIA:\n\nPatients are not eligible if they meet one or more of the following criteria:\n\n1. Age ≥ 80 years\n2. Obvious non-cardiac causes to cardiac arrest\n3. Obvious already hypothermic\n4. Obvious barrier to placing intra nasal catheters\n5. Have a known Do Not Attempt to Resuscitate (DNAR) order or other limitations in care\n6. Have a known terminal disease\n7. Known or clinically apparent pregnancy","79 Years",{"count":79,"type":19},1022,[53],"The aim of this clinical trial is to study the impact of ultra-early transnasal evaporative cooling after cardiac arrest and subsequent hypothermia at hospital, on survival with complete neurologic recovery, compared to currently recommended normothermia. The study population will consist of patients 18-79 years old, with out-of-hospital cardiac arrest with initial shockable rhythm.\n\nThe main research question it aims to answer is whether there is a difference in survival with complete neurologic recovery at 90 days after cardiac arrest between the group of patients that received ultra-early cooling, compared to the group that was treated with normothermia.\n\nParticipants will be randomized to two groups. One group (the intervention group) will receive ultra-early trans-nasal evaporative cooling initiated by EMS personnel at the scene of the cardiac arrest, and subsequent systemic hypothermia for 24 hours at hospital arrival. The other group (the control group), will receive standard of care (advanced cardiac life support and normal body temperature (normothermia)).",[83,25,84],"Out-Of-Hospital Cardiac Arrest","Ventricular Fibrillation",[86,87,88,89,90,91],"Therapeutic hypothermia","transnasal cooling","neurologic outcome","ultrafast hypothermia","prehospital","ECPR","2025-09-19",{"date":94,"type":30},"2025-09-25",{"date":96,"type":30},"2024-03-27",{"date":98,"type":19},"2028-05",{"name":100,"class":37},"Karolinska Institutet",11,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":51,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100537895","the-effect-of-warmed-socks-developed-as-wearable-technology-on-hypothermia-thermal-comfort-perception-and-shivering-100537895","NCT06283771","The Effect of Warmed Socks Developed as Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering","The Effect of Warmed Socks Developed as Wearable Technology on Hypothermia, Thermal Comfort Perception and Shivering in Healthy Volunteers","Inclusion Criteria:\n\n* -Written and verbal permission to participate in the study was obtained,\n* No communication problems,\n* Speaks and understands Turkish,\n* Non-hypothermic,\n* Not diagnosed with a chronic disease,\n* Not allergic to sock material,\n* No peripheral vascular disease,\n* Without a device that sends electric current into the body (pacemaker, etc.),\n* Healthy volunteers with a body mass index within normal limits (18.5-24.9 kg\u002Fm2).\n\nExclusion Criteria:\n\n* Written and verbal permission to participate in the research could not be obtained,\n* Communication problems,\n* Speaking Turkish but not understanding it,\n* Diagnosed with a chronic disease,\n* Hypothermic,\n* Peripheral vascular disease,\n* Allergic to sock material,\n* A person with a device (pacemaker, etc.) that sends electric current into the body,\n* Healthy volunteers with a body mass index not within normal limits (\\\u003C18.5 kg\u002Fm2- \\>25 kg\u002Fm2)",true,{"count":111,"type":19},70,[53],"In this study, it is aimed to reveal the effect of the use of heated socks to be developed as wearable technology by providing temperature control on body temperature, comfort perception level and shivering development in healthy volunteers and this purpose constitutes the unique value of the project. The research was planned as a prospective, two-arm (1:1), randomized controlled, double-blind study. The population of the study will consist of 4th year nursing students consisting of an average of 250 people who will enroll in the fall semester of the 2024-2025 academic year. As a result of the power analysis performed in the G\\*Power program, the sample will consist of 70 healthy volunteers, at least 35 in each group. In the study, data will be collected with the \"Descriptive Characteristics Form\" and \"Hypothermia Monitoring Form (Shivering Level Diagnosis Form and Temperature Comfort Perception Scale)\" which includes the descriptive information of healthy volunteers. Healthy volunteers will fill out the \"Introductory Characteristics Form\" and \"Hypothermia Monitoring Form\" before being taken to the Faculty of Nursing Skills Laboratory for the application. Before the volunteers are taken to the single rooms in the laboratory, the environment will be cooled for 30 minutes with the air conditioner in the room so that the temperature is 21oC. The study group will wear socks developed with wearable technology and the control group will wear socks with the same appearance. The healthy volunteer will be asked to lie motionless on the bed for 60 minutes in a single room. Body temperature (with Braun tympanic thermometer), shivering level and temperature comfort perception will be recorded on the \"Hypothermia Monitoring Form\" when all healthy volunteers are taken to the Skills Laboratory, at 15 minutes, 30 minutes and 60 minutes, and when they leave the laboratory. The research data will be analyzed in a computer environment. Descriptive variables of healthy volunteers included in the study will be expressed as mean±standard deviation and median (maximum minimum), percentage and frequency. Changes in body temperature measurements obtained after wearing socks to be developed with wearable technology, repeated measurements, analysis of variance (Repeated ANOVA) if parametric, Friedman test if non-parametric, and post-hoc test will be used in intra-group multiple comparison analysis as further analy",[115,25,116,117],"Wearable Technology","Shivering","Thermal Comfort Perception","NOT_YET_RECRUITING","2025-09-02",{"date":121,"type":30},"2025-09-09",{"date":123,"type":19},"2025-12-15",{"date":125,"type":19},"2026-09-15",{"name":127,"class":37},"Tarsus University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":51,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100553387","safety-and-efficacy-of-selective-intra-arterial-cooling-infusion-combined-with-evt-in-acute-ischemic-stroke-100553387","NCT06485427","Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke","Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With Endovascular Thrombectomy in Acute Ischemic Stroke: A Multicenter, Randomized Controlled, Subject- and Assessor-Blind Clinical Trials","FOCUS","Inclusion Criteria\n\n1. Age ≥ 18 and ≤ 80.\n2. Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA\u002FMRA\u002FDSA.\n3. NIHSS score obtained prior to randomization ≥ 6 and ≤ 25.\n4. Modified Rankin Scale ≤ 1 prior to qualifying stroke.\n5. Arterial puncture performed within 24 hours from symptom onset or LKW.\n6. For the patients with symptom onset within 6 hours, the ASPECT score ≥ 6; for the patients with onset within 6-24 hours, the therapy should meet the imaging criteria of DAWN or DEFUSE-3 trial.\n7. Patient\u002FLegally Authorized Representative has signed the Informed Consent Form.\n\nExclusion Criteria\n\n1. Baseline CT\u002FMRI confirms the presence of multiple vascular territory acute strokes.\n2. Baseline CT\u002FMRI confirms the presence of arterial dissection.\n3. Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.\n4. Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and\u002For anesthetics.\n5. Severe infection (e.g. sepsis) or multiple organ failure.\n6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \\> 3. Patients on factor Xa inhibitor for 48 hours ago must have a normal APTT.\n7. Baseline platelet count \\\u003C 50 × 10\\^9\u002FL.\n8. Blood glucose concentration\\\u003C50 mg\u002FdL (2.7 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL).\n9. Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg).\n10. Previous NHYA\\>1.\n11. Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.\n12. Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate \\\u003C 30 mL\u002Fmin or serum creatinine \\>220 mmol\u002FL (2.5 mg\u002FdL).\n13. Known intracranial aneurysm, and cerebral arteriovenous malformation.\n14. Malignant brain tumor or CNS infection.\n15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)\n16. Female who is pregnant or lactating at time of admission.\n17. Anticipated life expectancy \\\u003C 6 months.\n18. Current participation in another investigational drug or device study.\n19. For other reasons, the responsible clinicians believe that the patient is not suitable for continued treatment.","80 Years",{"count":138,"type":19},258,[53],"This is a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The research objective is to evaluate the safety and efficacy of selective intra-arterial cooling infusion combined with endovascular therapy in the treatment of acute anterior circulation large vessel occlusion stroke. This trial aims to enroll 258 subjects. Patients assigned to the control group will receive best medical management (BMM) and endovascular therapy (EVT). Those in the selective intra-arterial cooling infusion group (IA-SCI group) will undergo selective intra-arterial cold saline infusion, in addition to BMM and EVT. Subjects will be interviewed face-to-face at randomization, 24±6 hours, 48±6 hours after randomization, 7±2 days\u002Fdischarge. Telephone interviews\u002F face-to face interviews will be performed at 30±3 days and 90±7 days after randomization. The primary outcome is the distribution of Modified Rankin Score at 90±7days after randomization.",[142,25],"Acute Ischemic Stroke","2025-04-02",{"date":145,"type":30},"2025-04-04",{"date":147,"type":30},"2024-07-03",{"date":149,"type":19},"2026-08-01",{"name":151,"class":37},"Beijing Shijitan Hospital, Capital Medical University",9,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":109,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":51,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":38},"100452371","blood-warming-in-preterm-infants-to-decrease-hypothermia-100452371","NCT05170633","Blood Warming in Preterm Infants to Decrease Hypothermia","Evaluation of a Blood Warming Device for Packed Red Blood Cell Transfusions to Decrease Hypothermia in Very Preterm Infants","Inclusion Criteria:\n\n* Any infant born at PRISMA Health Richland hospital\n* less than 32 weeks gestational age by obstetrical dating as indicated in the electronic medical chart\n* admitted to the neonatal intensive care unit receiving one PRBC transfusion within the first month of life.\n\nExclusion Criteria:\n\n* Infants having neurological anatomical abnormalities or major brain hemorrhage (Grade III or IV), because neurological damage can interfere with thermal control.","24 Weeks","32 Weeks",{"count":163,"type":19},140,[53],"Background\u002Fsignificance: Over 100,000 early preterm infants are born annually in the United States and suffer morbidity and mortality during hospitalization in a neonatal intensive care unit. One such condition is hypothermia. Hypothermia has been defined as a contributor of neonatal morbidity by The World Health Organization. Another acute morbidity is anemia in preterm infants due to the prematurity and frequent laboratory testing. Anemia requires correction with a packed red blood cells (PRBC) transfusion.\n\nResearchers have previous noted hypothermia during PRBC transfusions in preterm infants. Objective: To use a commercial blood warmer in the neonatal intensive care setting to prevent hypothermic body temperatures (\\\u003C36.5°C) in very preterm infants during PRBC transfusions.\n\nProcess: Based on a completed national survey of neonatal intensive care nurses and PRBC transfusion practices and personal NICU experience, we designed this randomized control trial in 140 very preterm infants in a Southeastern, level III neonatal intensive care unit.\n\nOutcomes: Very preterm infants (\\\u003C32 weeks gestational age) receiving PRBC transfusions warmed by the commercial blood warmer will have a lower incidence of central body hypothermia post transfusion (temperatures \\\u003C36.5C), compared to infants receiving PRBC transfusions by standard of care. Very preterm infants (\\\u003C32 weeks gestational age) receiving PRBC transfusions warmed by the commercial blood warmer will have a higher post transfusion mean abdominal skin body temperature when compared to infants receiving PRBC transfusions by standard of care.\n\nHypothesis : The results of this trial could show that very preterm infants experience hypothermia during PRBC transfusions, and thus provide the evidence to support the need for warmed PRBC transfusions in very preterm infants nationwide.",[167,168,25],"Preterm Birth","Blood Transfusion Complication","2024-12-05",{"date":171,"type":30},"2024-12-11",{"date":173,"type":30},"2022-01-01",{"date":175,"type":19},"2026-01-01",{"name":177,"class":37},"University of South Carolina"]